EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 768 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Melphalan October 1, 2020 Let’s get to the bottom of it – 7 common cancer... January 4, 2022 Cancer in My Community: The Role of Cancer Screening in Guatemala November 5, 2020 Efficacy and Safety of Elranatamab, BCMA-CD3 Bispecific Antibody, in Patients with... August 28, 2023 Load more HOT NEWS Picking out the patterns: How scientists are finding cancer’s signatures in... Interpreted cancer awareness workshops: talking about cancer with South-Asian communities Immune interception represents an exciting opportunity to stop cancer in its... Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom...
